Tags

Type your tag names separated by a space and hit enter

Dopamine agonists in Parkinson's disease.
Expert Rev Neurother. 2008 Apr; 8(4):671-7.ER

Abstract

Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson's disease (PD) throughout its course. As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications. As an adjunct to levodopa, they improve motor control and limit the need for levodopa in those patients in whom this may be considered relevant. The non-ergot dopamine agonists in particular have a good safety profile, although as with other agonists, sedation, and cognitive and behavioral problems may be limiting in some patients. Pramipexole has shown benefit in improving depressive symptoms in PD. Ropinirole and pramipexole have both demonstrated a reduction in the rate of loss of nigrostriatal innervation as determined by imaging in PD patients, when compared with levodopa. Thus, dopamine agonists contribute to several dimensions of the management of PD and have become an integral part of the disease treatment algorithm.

Authors+Show Affiliations

Department of Neurology, Kagawa, Prefectural Central Hospital, Takamatsu, Japan.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18416667

Citation

Yamamoto, Mitsutoshi, and Anthony H V. Schapira. "Dopamine Agonists in Parkinson's Disease." Expert Review of Neurotherapeutics, vol. 8, no. 4, 2008, pp. 671-7.
Yamamoto M, Schapira AH. Dopamine agonists in Parkinson's disease. Expert Rev Neurother. 2008;8(4):671-7.
Yamamoto, M., & Schapira, A. H. (2008). Dopamine agonists in Parkinson's disease. Expert Review of Neurotherapeutics, 8(4), 671-7. https://doi.org/10.1586/14737175.8.4.671
Yamamoto M, Schapira AH. Dopamine Agonists in Parkinson's Disease. Expert Rev Neurother. 2008;8(4):671-7. PubMed PMID: 18416667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dopamine agonists in Parkinson's disease. AU - Yamamoto,Mitsutoshi, AU - Schapira,Anthony H V, PY - 2008/4/18/pubmed PY - 2008/5/29/medline PY - 2008/4/18/entrez SP - 671 EP - 7 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 8 IS - 4 N2 - Dopamine agonists are established as effective drugs for the symptomatic treatment of Parkinson's disease (PD) throughout its course. As monotherapy, they produce effective control of motor symptoms and combine this with a low risk for motor complications. As an adjunct to levodopa, they improve motor control and limit the need for levodopa in those patients in whom this may be considered relevant. The non-ergot dopamine agonists in particular have a good safety profile, although as with other agonists, sedation, and cognitive and behavioral problems may be limiting in some patients. Pramipexole has shown benefit in improving depressive symptoms in PD. Ropinirole and pramipexole have both demonstrated a reduction in the rate of loss of nigrostriatal innervation as determined by imaging in PD patients, when compared with levodopa. Thus, dopamine agonists contribute to several dimensions of the management of PD and have become an integral part of the disease treatment algorithm. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/18416667/Dopamine_agonists_in_Parkinson's_disease_ L2 - https://www.tandfonline.com/doi/full/10.1586/14737175.8.4.671 DB - PRIME DP - Unbound Medicine ER -